UCSF Immuno-Oncology Show Stellar Preclinical Results with Engineered Smart Immune Cells that Zap Brain Cancer Cells: Clinical Trials Coming

UCSF Immuno-Oncology Show Stellar Preclinical Results with Engineered Smart Immune Cells that Zap Brain Cancer Cells Clinical Trials Coming

University of California, San Francisco (UCSF) researchers focusing on immunotherapies that fight cancer center their attention on emerging engineered smart immune cells can zap solid cancerous tumors, opening the opportunity up to apply breakthrough immuno-oncology therapies targeting a number of cancers that up until now have been considered treatable with this powerful therapy harnessing the patient’s own immune system. Exemplified in two research papers published April 28, 2021 in Science Translational Medicine, the UCSF investigators suggest by “programming” basic computational abilities into immune cells engineered to zap cancerous tumors, they have figured out how to overcome considerable obstacles that have limited the use of these therapies in the clinic.  Advanced-programmed “smart” therapies are more targeted, precise yet flexible than the previous generation of immuno-oncology approaches. Coming soon: clinical trials based on this breakthrough.

TrialSite breaks this potentially exciting information down for the community.

Who are the two research authors?

In the first paper, Wendell Lim, PhD, chair and Byers Distinguished Professor of cellular and molecul...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee